Open AccessUse of fertility drugs in Denmark 1973–1993
Author(s) -
Mosgaard Berit,
Lidegaard øjvind,
Andersen Anders Nyboe
Publication year - 1995
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016349509013473
Subject(s) - medicine , gonadotropin , human chorionic gonadotropin , menotropins , ovulation , fertility , ovulation induction , gynecology , clomifene , hmg coa reductase , incidence (geometry) , stimulation , endocrinology , hormone , population , biology , environmental health , biochemistry , physics , optics , reductase , enzyme
Objectives. The increasing use of drugs for ovarian stimulation and the possibility of long‐term risks has actualized a quantitative assessment of the use of such therapy. The aim of the study was to analyze the development in the sale of different types of drugs used for ovarian stimulation in Denmark during the last two decades. Material. Sale statistics of clomiphene citrate, cyclophenile, human menopausal gonadotropin (hMG), mare menopausal gonadotropin (mMG) and human chorionic gonadotropin (hCG) in Denmark 1973–1993. Methods. The number of defined daily doses (DDD) was calculated for each product group. On given assumptions the number of cycles of different treatment regimens and the number of treated women was calculated. Results. The sale has increased almost exponentially throughout the last two decades: Clomiphene citrate 11 fold, hMG 30 fold, and hCG 5 fold. Today, among women 15–44 years old, the estimated incidence rate of women treated with clomiphene alone is about 2.7/1,000/year, and the incidence rate of women treated with clomiphene/hCG and hMG/hCG account for about 3.1/1,000/year and 1.9/1,000/year, respectively. Conclusion. Any study concerning short‐and long‐term effects of ovarian stimulation have to consider this secular trend.